Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 83

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Myasthenia gravis

Not recruiting

Study on the Safety and Tolerability of DNTH103 for Adults with Generalized Myasthenia Gravis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Subarachnoid haemorrhage

Not recruiting

Study on the Safety of EDV2209 for Patients with Brain Bleeding (Subarachnoid Hemorrhage)

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:1,4-Diamino-2,3-Dicyano-1,4-Bis(O-Aminophenylmercapto)Butadiene Hemiethanolate
  • Sponsor:Edvince AB

Giant cell arteritis

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Prednisolone in Patients with Giant Cell Arteritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cerebral palsy

Not recruiting

Study on Botulinum Toxin A and Hyoscine for Treating Drooling in Children Over 4 with Cerebral Palsy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Hyoscine
  • Sponsor:Hospices Civils De Lyon

Ischaemic stroke

Not recruiting

Study on the Effectiveness of Dornase Alfa for Improving Blood Flow in Patients with Ischemic Stroke Eligible for Thrombectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dornase Alfa
  • Sponsor:Fondation A De Rothschild

Neuralgia+1

Not recruiting

Study on Lacosamide and Duloxetine for Patients with Chemotherapy-Induced Neuropathic Pain

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Duloxetine
  • Sponsor:Leiden University Medical Center

Huntington's disease

Not recruiting

Study on the Safety and Effects of AMT-130 for Adults with Early Huntington's Disease

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ifezuntirgene Inilparvovec
  • Sponsor:uniQure biopharma B.V.

Duchenne muscular dystrophy

Not recruiting

Study on the Effects of ATL1102 for Nonambulatory Patients with Duchenne Muscular Dystrophy

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:2'-O-(2-METHOXYETHYL) phosphorothioate antisense oligonucleotide targeting CD49D RNA
  • Sponsor:Antisense Therapeutics Limited

Multiple sclerosis

Not recruiting

Study on Personalized Dosing of Natalizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Natalizumab
  • Sponsor:Amsterdam UMC Stichting

Metastases to central nervous system

Not recruiting

Study on 68Ga-NOTA-Anti-HER2 VHH1 for Cancer Patients with Brain Metastasis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:68GANOTA-anti-HER2 VHH1
  • Sponsor:UZ Brussel

Cognitive disorder+1

Not recruiting

Study on the Effects of Lamivudine on Cognitive Impairment in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lamivudine
  • Sponsor:Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia

Impaired gastric emptying+1

Not recruiting

Study on the Safety and Effectiveness of Naronapride for Adults with Moderate Idiopathic or Diabetic Gastroparesis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Naronapride Dihydrochloride Trihydrate
  • Sponsor:Dr. Falk Pharma GmbH

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.